Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma

被引：5

作者：

Ponto, Jay ^{[1
]}

Bell, R. Bryan ^{[1
]}

机构：

[1] Providence Canc Inst, Earle A Chiles Res Inst, Robert W Franz Canc Ctr, 4805 NE Glisan St Suite 2N35, Portland, OR 97213 USA

来源：

ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA | 2022年 / 34卷 / 02期

关键词：

Melanoma; Immunotherapy; Adaptive therapy; Head and neck; Metastasis; Systemic therapy; Malignancy; STAGE-III MELANOMA; DABRAFENIB PLUS TRAMETINIB; LONG-TERM SURVIVAL; DOUBLE-BLIND; HIGH-RISK; IV MELANOMA; RECOMBINANT INTERLEUKIN-2; COMPLETE RESECTION; BRAF INHIBITION; POOLED ANALYSIS;

D O I：

10.1016/j.coms.2021.11.010

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

[No abstract available]

引用

页码：315 / 324

页数：10

共 65 条

[11] Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
Curti, Brendan
Crittenden, Marka
Seung, Steven K.
Fountain, Christopher B.
Payne, Roxanne
Chang, ShuChing
Fleser, Jessica
Phillips, Kimberly
Malkasian, Ian
Dobrunick, Lyn B.
Urba, Walter J.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[12] Recent Advances in the Treatment of Melanoma
Curti, Brendan D.
Faries, Mark B.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (23) : 2229 - 2240
[13] Mutations of the BRAF gene in human cancer
Davies, H
Bignell, GR
Cox, C
Stephens, P
Edkins, S
Clegg, S
Teague, J
Woffendin, H
Garnett, MJ
Bottomley, W
Davis, N
Dicks, N
Ewing, R
Floyd, Y
Gray, K
Hall, S
Hawes, R
Hughes, J
Kosmidou, V
Menzies, A
Mould, C
Parker, A
Stevens, C
Watt, S
Hooper, S
Wilson, R
Jayatilake, H
Gusterson, BA
Cooper, C
Shipley, J
Hargrave, D
Pritchard-Jones, K
Maitland, N
Chenevix-Trench, G
Riggins, GJ
Bigner, DD
Palmieri, G
Cossu, A
Flanagan, A
Nicholson, A
Ho, JWC
Leung, SY
Yuen, ST
Weber, BL
Siegler, HF
Darrow, TL
Paterson, H
Marais, R
Marshall, CJ
Wooster, R
[J]. NATURE, 2002, 417 (6892) : 949 - 954
[14] Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Dummer, Reinhard
Hauschild, Axel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Kirkwood, John M.
Sileni, Vanna Chiarion
Larkin, James
Nyakas, Marta
Dutriaux, Caroline
Haydon, Andrew
Robert, Caroline
Mortier, Laurent
Schachter, Jacob
Lesimple, Thierry
Plummer, Ruth
Dasgupta, Kohinoor
Gasal, Eduard
Tan, Monique
Long, Georgina V.
Schadendorf, Dirk
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12) : 1139 - 1148
[15] Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Dummer, Reinhard
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
Sileni, Vanna Chiarion
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
Moutouh-de Parseval, Laure A.
Pickard, Michael D.
Sandor, Victor
Roberti, Caroline
Flaherty, Keith T.
[J]. LANCET ONCOLOGY, 2018, 19 (10) : 1315 - 1327
[16] Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Dummer, Reinhard
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
Chiarion-Sileni, Vanna
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
Moutouh-de Parseval, Laure A.
Pickard, Michael D.
Sandor, Victor
Robert, Caroline
Flaherty, Keith T.
[J]. LANCET ONCOLOGY, 2018, 19 (05) : 603 - 615
[17] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M.
Chiarion-Sileni, V.
Grob, J. -J.
Dummer, R.
Wolchok, J. D.
Schmidt, H.
Hamid, O.
Robert, C.
Ascierto, P. A.
Richards, J. M.
Lebbe, C.
Ferraresi, V.
Smylie, M.
Weber, J. S.
Maio, M.
Bastholt, L.
Mortier, L.
Thomas, L.
Tahir, S.
Hauschild, A.
Hassel, J. C.
Hodi, F. S.
Taitt, C.
de Pril, V.
de Schaetzen, G.
Suciu, S.
Testori, A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1845 - 1855
[18] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Eggermont, Alexander M. M.
Suciu, Stefan
Santinami, Mario
Testori, Alessandro
Kruit, Wim H. J.
Marsden, Jeremy
Punt, Cornelis J. A.
Sales, Francois
Gore, Martin
MacKie, Rona
Kusic, Zvonko
Dummer, Reinhard
Hauschild, Axel
Musat, Elena
Spatz, Alain
Keilholz, Ulrich
[J]. LANCET, 2008, 372 (9633) : 117 - 126
[19] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Giacomo, Anna Maria Di
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
[J]. LANCET ONCOLOGY, 2021, 22 (05) : 643 - 654
[20] Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
Eggermont, Alexander M. M.
Bellomo, Domenico
Arias-Mejias, Suzette M.
Quattrocchi, Enrica
Sominidi-Damodaran, Sindhuja
Bridges, Alina G.
Lehman, Julia S.
Hieken, Tina J.
Jakub, James W.
Murphree, Dennis H.
Pittelkow, Mark R.
Sluzevich, Jason C.
Cappel, Mark A.
Bagaria, Sanjay P.
Perniciaro, Charles
Tjien-Fooh, Felicia J.
Rentroia-Pacheco, Barbara
Wever, Renske
van Vliet, Martin H.
Dwarkasing, Jvalini
Meves, Alexander
[J]. EUROPEAN JOURNAL OF CANCER, 2020, 140 : 11 - 18

← 1 2 3 4 5 6 7 →